Worth reading
45Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
529
Millions of yen (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter1 April 2025 to 31 December 2025Non-consolidated (standalone)Japanese GAAPNet Sales7,310¥ millionYear on year +25.9%Progress 73.1%
Operating profit187¥ millionProgress 93.5%
Ordinary income222¥ millionProgress 88.8%
Net income attributable to owners of the parent215¥ millionProgress 107.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share6.19円
Financial position at period-end
Total assets15,840¥ million
of which net assets 12,091 ¥ millionEquity ratio 76.3%vs. prior year-end -1.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenuePharmaceuticals ¥3,464,903 thousand (YoY +38.2%), Healthcare Business ¥1,915,309 thousand (YoY +5.0%), Global Business ¥1,789,908 thousand (YoY +33.4%), Real estate leasing ¥140,332 thousand (YoY +4.8%)
Segment profitPharmaceuticals ¥-547,503 thousand, Healthcare Business ¥279,718 thousand, Global Business ¥407,273 thousand, Real estate leasing ¥48,341 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥10,000 million (YoY +28.4%)
Operating profit¥200 million
Ordinary income¥250 million
Net income¥200 million (YoY +210.4%)
Annual Dividend Forecast¥3 → ¥3（0.0%）
Factors Behind Changes in Business Performance
「強力わかもと」の販売数量増加、「マキュエイド眼注用」の供給再開、後発医薬品等の売上伸長、店頭・デジタル販促、中国越境ECのSNSプロモーションなどにより売上高が増加した。広告宣伝費や販売費の増加もあった。
Disclosure regarding the going concern assumption
Not applicable
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Breakdown of extraordinary income (loss)当第3四半期累計期間は特別利益・特別損失ともに計上なし
Depreciation and amortization¥328,658 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End34,838,325
Treasury Shares at Period-End132,397
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025 to 31 December 2025 |
| Net Sales | ¥7,310 million (YoY +25.9%) |
| Operating profit | ¥187 million |
| Ordinary income | ¥222 million |
| Profit attributable to owners of the parent | ¥215 million |
| Net income per share | 6.19円 |
| Equity ratio | End of the current fiscal period 76.3 / End of previous period 77.4 |
| Total assets | ¥15,840 million |
| Net assets | ¥12,091 million |
| Full-year earnings forecast | Net Sales ¥10,000 million (YoY +28.4%) / Operating profit ¥200 million / Ordinary income ¥250 million / Net income ¥200 million (YoY +210.4%) |
| Annual Dividend Forecast | ¥3 → ¥3（0.0%） |
| Segment revenue | Pharmaceuticals ¥3,464,903 thousand (YoY +38.2%), Healthcare Business ¥1,915,309 thousand (YoY +5.0%), Global Business ¥1,789,908 thousand (YoY +33.4%), Real estate leasing ¥140,332 thousand (YoY +4.8%) |
| Segment profit | Pharmaceuticals ¥-547,503 thousand, Healthcare Business ¥279,718 thousand, Global Business ¥407,273 thousand, Real estate leasing ¥48,341 thousand |
| Depreciation and amortization | ¥328,658 thousand |
| Breakdown of extraordinary income (loss) | 当第3四半期累計期間は特別利益・特別損失ともに計上なし |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 34,838,325 |
| Treasury Shares at Period-End | 132,397 |
| Factors Behind Changes in Business Performance | 「強力わかもと」の販売数量増加、「マキュエイド眼注用」の供給再開、後発医薬品等の売上伸長、店頭・デジタル販促、中国越境ECのSNSプロモーションなどにより売上高が増加した。広告宣伝費や販売費の増加もあった。 |
Items this document does not state (13)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossChanges in the scope of consolidationMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.「強力わかもと」の販売数量増加や、「マキュエイド眼注用」の供給再開などにより売上高が増加した。一方、商品リニューアルや新商品の発売に伴い広告宣伝費・販売費も増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.